2 active not recruiting, 2 recruiting, 2 terminated. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Recruiting 2, Terminated 2 |
Follow Castration-Sensitive Prostate Carcinoma: new trials by email Literature Review of Castration-Sensitive Prostate Carcinoma trials Research Report on Castration-Sensitive Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial Antiandrogen Therapy, Bone Scan, Computed Tomography - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2024-02-18 | 2026-10-08 |
| Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration - Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 79 | 2022-11-21 | 2026-09-24 |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Abiraterone Acetate, Bicalutamide, Degarelix - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 70 | 2021-05-04 | 2026-01-28 |
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer Antiandrogen Therapy, Abiraterone Acetate, Prednisone - Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Terminated | University of Washington | 10 | 2020-06-29 | 2023-10-26 |
| Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer Abiraterone Acetate, Antiandrogen Therapy, Apalutamide - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 7 | 2020-05-11 | 2026-07-15 |
| Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer Abiraterone Acetate, Antiandrogen Therapy, Docetaxel - Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma | Phase 2 | Terminated | University of Utah | 1 | 2019-02-08 | 2020-06-25 |
Genital Diseases (6) · Genital Diseases, Male (6) · Genital Neoplasms, Male (6) · Male Urogenital Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Prostatic Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6)
Abiraterone Acetate (4) · Androgen Antagonists (4) · Prednisone (4) · deltacortene (3) · prednylidene (3) · Radiation (2) · Radiotherapy (2) · Cytotoxins (1) · Docetaxel (1) · Goserelin (1) · Leuprolide (1) · Specimen Handling (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · apalutamide (1) · bicalutamide (1)
Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · University of Utah (1) · University of Washington (1)
United States (6)
Atish D. Choudhury, MD, PhD (1) · Benjamin Maughan, MD (1) · David VanderWeele, MD, PhD (1) · Jing Zeng (1) · Julie Graff, MD (1) · Tanya Dorff (1)
P30CA033572 (1), P30CA060553 (1), P50CA097186 (1), U10CA180821 (1)